U.S. benefits manager baulks after Novartis values gene therapy at $4-5 million

Just weeks after Novartis floated the idea that $4-5 million was fair value for its new gene therapy against a deadly neuromuscular disease, a major benefits manager is pushing back.


from Reuters: Health News https://ift.tt/2DThv1l

No comments:

Post a Comment

Teen struggling w/ weight + no support at home, where the hell do I even start?

So I’m a teenager and I’ve been overweight/obese basically my whole life. And it’s been messing with me pretty bad. For the record, I don’...